PEComa Epidemiology Forecasts, 2032 - Focus on 7 Major Markets - United States, Germany, Spain, Italy, France, United Kingdom, and Japan
Wednesday, June 21, 2023
DUBLIN, June 15, 2023 /PRNewswire/ -- The "PEComa - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This report delivers an in-depth understanding of the PEComa, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
PEComa Epidemiology
As the market is derived using a patient-based model, the PEComa epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of PEComa, PEComa cases by Gender, Stage, Clinical Presentation, and Age in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.
-- The total number of incident cases of PEComa in the United States was
around 250 cases in 2022 and is projected to increase during the
forecast period (2023-2032).
-- The United States contributed to the largest incident population of
PEComa, acquiring ~64% of the 7MM in 2022. Whereas EU4 and the UK, and
Japan accounted for around 28% and 8% of the total population share,
respectively, in 2022.
-- Among the EU4 countries, Germany accounted for the largest number of
PEComa cases, followed by France, whereas Spain accounted for the lowest
number of cases in 2022.
-- According to the publisher estimates, there were more patients in the
benign stage as compared to the malignant PEComa in the United States in
2022. The incidence is projected to increase during the forecast period.
-- In the 7MM, approximately 70% of the patient share is attributed to
females, whereas only 30% of males suffer from PEComa.
KOL Views
To keep up with current trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on PEComa evolving diagnostic landscape, include Medical/scientific writers, Medical Oncologists, and Professors, Department of Medical Oncology, Strasbourg-Europe Cancer Institute, Dana-Farber Cancer Institute, and others.
This analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as MD Anderson Cancer Center, Texas from UT Southwestern Medical Center in Dallas, Cancer Research UK Barts Centre in London, MD Anderson Cancer Center, etc., were contacted. Their opinion helps understand and validate current diagnostic patterns.
Key Highlights:
-- The total number of incident cases of PEComa in the United States was
around 250 cases in 2022 and is projected to increase during the
forecast period (2023-2032).
-- The United States contributed to the largest incident population of
PEComa, acquiring ~64% of the 7MM in 2022. Whereas EU4 and the UK, and
Japan accounted for around 28% and 8% of the total population share,
respectively, in 2022.
-- Aadi Bioscience's FYARRO is the only approved therapy for PEComa.
PEComa Report Insights
-- Patient Population
-- Patient population by gender, stage, and age
-- Country-wise Epidemiology Distribution
PEComa Report Key Strengths
-- Ten Years Forecast
-- The 7MM Coverage
-- PEComa Epidemiology Segmentation
PEComa Report Assessment
-- Epidemiology Segmentation
-- Current Diagnostic Practices
Epidemiology Insights:
-- What are the disease risk, burdens, and unmet needs of PEComa? What will
be the growth opportunities across the 7MM with respect to the patient
population pertaining to PEComa?
-- What is the historical and forecasted PEComa patient pool in the United
States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and
Japan?
-- Which type of molecular alterations associated with PEComas contributes
the most in patients affected with PEComa?
-- What is the contribution of benign and malignant cases in total incident
cases PEComa?
Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology Forecast Methodology
6. PEComa Epidemiology Overview at a Glance in the 7MM
6.1. Patient Share (%) of PEComa in 2022
6.2. Patient Share (%) of PEComa in 2032
7. Disease Background and Overview
7.1. Introduction
7.1.1. Subtypes of PEComas
7.1.2. Signs and symptoms
7.1.3. Causes
7.1.4. Risk assessment
7.1.5. Pathomorphology
7.2. Diagnosis
7.2.1. Immunohistochemistry
7.3. Differential Diagnosis
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumption and Rationale
8.3. Total Incident Cases of PEComa in the 7MM
8.4. US
8.4.1. Total Incident Cases of PEComa in the US
8.4.2. PEComa Cases by Gender in the US
8.4.3. PEComa Cases by Stage in the US
8.4.4. PEComa Cases by Clinical Presentation in the US
8.4.5. PEComa Cases by Age in the US
8.5. EU4 and the UK
8.6. Japan
9. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/s50tqk
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/pecoma-epidemiology-forecasts-2032---focus-on-7-major-markets---united-states-germany-spain-italy-france-united-kingdom-and-japan-301851791.html
SOURCE Research and Markets
|
|
|
|
|
 |
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
The Roadmap to Securing Your Own Digital Domain is Now Available | Jan 22, 2026
|
|
|
